{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:05:14Z","timestamp":1789427114651,"version":"build-2803163510"},"reference-count":94,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global rise in aging populations has been accompanied by increasing rates of\n                    obesity and type 2 diabetes, both of which pose significant public health and\n                    economic challenges. This review aims to investigate the pathophysiological link\n                    between obesity and diabetes and evaluate emerging therapeutic strategies that\n                    involve glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists,\n                    including their dual and triple agonist developments. A comprehensive literature\n                    review was conducted focusing on the mechanisms of glucagon-like peptide-1\n                    receptor and melanocortin-4 receptor agonists, their clinical efficacy, and the\n                    evolution of combination therapies. Emphasis was placed on recent clinical\n                    trials and the development of oral agonist formulations to improve patient\n                    compliance. Glucagon-like peptide-1 receptor agonists, such as semaglutide and\n                    liraglutide, promote insulin secretion, suppress appetite, and result in\n                    effective weight loss and glycemic control. Semaglutide is available in both\n                    injectable and oral forms, improving accessibility. Liraglutide also reduces\n                    cardiovascular risk. Melanocortin-4 receptor agonists act via the central\n                    nervous system to reduce appetite and increase energy expenditure, with\n                    setmelanotide showing efficacy in genetic obesity. Dual and triple agonists,\n                    such as tirzepatide, simultaneously target glucagon-like peptide-1,\n                    glucose-dependent insulinotropic polypeptide, and glucagon receptors, leading to\n                    enhanced metabolic outcomes. Oral drugs like rybelsus improve long-term\n                    adherence. Glucagon-like peptide-1 receptor and melanocortin-4 receptor\n                    agonists, particularly when used as dual or triple agents, represent promising\n                    therapeutic innovations for obesity and type 2 diabetes. The development of oral\n                    formulations further enhances treatment convenience and adherence, paving the\n                    way for improved clinical outcomes.<\/jats:p>","DOI":"10.1055\/a-2928-5204","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:32:36Z","timestamp":1788561156000},"page":"339-353","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in Glucagon-Like Peptide-1 Receptor and\n                    Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2\n                    Diabetes"],"prefix":"10.1055","volume":"58","author":[{"given":"Chang-Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Chosun University, South Korea","place":["Gwangju"],"department":["Department of Biological Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Chosun University, South Korea","place":["Gwangju"],"department":["Department of Biological Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hyun","family":"Shim","sequence":"additional","affiliation":[{"name":"Chosun University, South Korea","place":["Gwangju"],"department":["Department of Biological Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-5095","authenticated-orcid":false,"given":"Gwang-Won","family":"Cho","sequence":"additional","affiliation":[{"name":"Chosun University, South Korea","place":["Gwangju"],"department":["Department of Biological Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1038\/s41467-024-47197-5","article-title":"Global projections of heat exposure of older adults","volume":"15","author":"G Falchetta","year":"2024","journal-title":"Nat Commun"},{"issue":"05","key":"ref2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.bpobgyn.2013.02.005","article-title":"The clinical consequences of an ageing world and preventive strategies","volume":"27","author":"B Lunenfeld","year":"2013","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","article-title":"Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic\n                    diseases and aging","volume":"97","author":"K Jomova","year":"2023","journal-title":"Arch Toxicol"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41366-024-01529-z","article-title":"Obesity pharmacotherapy in older adults: a narrative review of evidence","volume":"49","author":"A E Henney","year":"2025","journal-title":"Int J Obes (Lond)"},{"issue":"17","key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of Type 2 Diabetes Mellitus","volume":"21","author":"U Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"04","key":"ref6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s13679-023-00527-y","article-title":"Update on the obesity epidemic: After the sudden rise, is the upward trajectory\n                    beginning to flatten","volume":"12","author":"C Koliaki","year":"2023","journal-title":"Curr Obes Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"706978","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: Epidemiology, pathophysiology, and therapeutics","volume":"12","author":"X Lin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"03","key":"ref8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10552-017-0869-z","article-title":"Energy balance and obesity: what are the main drivers","volume":"28","author":"I Romieu","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"11","key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119677","article-title":"Type 2 diabetes mellitus, non-alcoholic fatty liver disease, and metabolic\n                    repercussions: The vicious cycle and its interplay with inflammation","volume":"24","author":"R Frankowski","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"02","key":"ref10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.18632\/aging.100431","article-title":"Inflammatory cause of metabolic syndrome via brain stress and NF-\u03baB","volume":"4","author":"D Cai","year":"2012","journal-title":"Aging (Albany NY)"},{"issue":"17","key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/nu15173728","article-title":"The mechanism of the gut-brain axis in regulating food intake","volume":"15","author":"S Li","year":"2023","journal-title":"Nutrients"},{"issue":"11","key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119328","article-title":"An update on the molecular and cellular basis of pharmacotherapy in type 2\n                    diabetes mellitus","volume":"24","author":"M O Mahgoub","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"X Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: Insights into mechanisms and therapeutic\n                    strategy","volume":"7","author":"M Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biology9120473","article-title":"Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic\n                    Approaches","volume":"9","author":"G A Boer","year":"2020","journal-title":"Biology (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.12688\/f1000research.8300.2","article-title":"Complex mechanisms linking neurocognitive dysfunction to insulin resistance and\n                    other metabolic dysfunction","volume":"5","author":"L E Stoeckel","year":"2016","journal-title":"F1000Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus:\n                    connections in epidemiology, pathogenesis, and\n                    treatments","volume":"14","author":"R Ruze","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"03","key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032227","article-title":"Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility\n                    of Brown Adipose Tissue as a Therapeutic Target","volume":"24","author":"K Ziqubu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"05","key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054405","article-title":"Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor\n                    Empagliflozin among Patients with Obesity and Type 2 Diabetes","volume":"24","author":"Z Szekeres","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-022-01149-x","article-title":"Signaling pathways in obesity: mechanisms and therapeutic interventions","volume":"7","author":"X Wen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1\/3","key":"ref22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.regpep.2007.03.002","article-title":"Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via\n                    increased insulin secretion","volume":"143","author":"D Hagemann","year":"2007","journal-title":"Regul Pept"},{"issue":"07","key":"ref23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/sj.bjp.0706929","article-title":"The MC4 receptor and control of appetite","volume":"149","author":"R A Adan","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"03","key":"ref24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.15252\/emmm.201404508","article-title":"Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic\n                    benefits in diet-induced obese mice","volume":"7","author":"C Clemmensen","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"15","key":"ref25","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1111\/jcmm.17441","article-title":"MC4R biased signalling and the conformational basis of biological function\n                    selections","volume":"26","author":"Z Liu","year":"2022","journal-title":"J Cell Mol Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.12688\/f1000research.20602.1","article-title":"Recent advances in understanding the role of glucagon-like peptide 1","volume":"9","author":"J Reed","year":"2020","journal-title":"F1000Res"},{"issue":"01","key":"ref27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-024-01923-z","article-title":"Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising\n                    target for incretin secretagogue therapies","volume":"9","author":"Y C Yuan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of\n                    Head-to-Head Clinical Trials","volume":"11","author":"M Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/JOE-11-0094","article-title":"Processing of proglucagon to GLP-1 in pancreatic \u03b1-cells: is this a paracrine\n                    mechanism enabling GLP-1 to act on \u03b2-cells?","volume":"211","author":"N M Whalley","year":"2011","journal-title":"J Endocrinol"},{"issue":"05","key":"ref30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/joim.13433","article-title":"Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic\n                    wizard congruent?","volume":"291","author":"J J Holst","year":"2022","journal-title":"J Intern Med"},{"issue":"04","key":"ref31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long\n                    March to Therapeutic Successes","volume":"68","author":"Cd Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"02","key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020751","article-title":"GLP-1R Signaling and Functional Molecules in Incretin Therapy","volume":"28","author":"W Wan","year":"2023","journal-title":"Molecules"},{"issue":"02","key":"ref33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and development of exenatide: the first antidiabetic agent to leverage\n                    the multiple benefits of the incretin hormone, GLP-1","volume":"8","author":"D G Parkes","year":"2013","journal-title":"Expert Opin Drug Discov"},{"issue":"01","key":"ref34","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1080\/10717544.2020.1850919","article-title":"Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a\n                    long-acting drug delivery system with improved release characteristics","volume":"27","author":"J Zhai","year":"2020","journal-title":"Drug Deliv"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"L B Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/DMSO.S174568","article-title":"Clinical potential of liraglutide in cardiovascular risk reduction in patients\n                    with type 2 diabetes: evidence to date","volume":"12","author":"R Howell","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"03","key":"ref37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1060028014564180","article-title":"Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2\n                    diabetes","volume":"49","author":"A M Thompson","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"03","key":"ref38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg\n                    in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled\n                    Trial (AWARD-11)","volume":"44","author":"J P Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"03","key":"ref39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular\n                    benefits for management of type 2 diabetes","volume":"23","author":"M K Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"24","key":"ref40","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"A M Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"ref41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and\n                    Obesity","volume":"389","author":"M N Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"02","key":"ref42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2\n                    Diabetes","volume":"391","author":"V Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"ref43","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated\n                    Steatohepatitis","volume":"392","author":"A J Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"M Yu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DMSO.S45379","article-title":"Clinical potential of lixisenatide once daily treatment for type 2 diabetes\n                    mellitus","volume":"6","author":"A B Petersen","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood\n                    brain barrier and enhance neurogenesis","volume":"13","author":"K Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1396656","DOI":"10.3389\/fphar.2024.1396656","article-title":"Glucagon-like peptide-1 receptor agonists: new\n                    strategies and therapeutic targets to treat atherosclerotic cardiovascular\n                    disease","volume":"15","author":"T Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"04","key":"ref48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/gutjnl-2013-306235","article-title":"Recent advances in clinical practice challenges and opportunities in the\n                    management of obesity","volume":"63","author":"A Acosta","year":"2014","journal-title":"Gut"},{"issue":"04","key":"ref49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"ref50","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a\n                    double-blind, randomised placebo-controlled trial","volume":"394","author":"H C Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"ref52","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"M A Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"ref53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2\n                    Diabetes","volume":"377","author":"R R Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"03","key":"ref54","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1152\/ajpendo.00434.2002","article-title":"The melanocortin system","volume":"284","author":"I Gantz","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"02","key":"ref55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.molmed.2018.12.002","article-title":"Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity\n                    Treatment","volume":"25","author":"P Kuhnen","year":"2019","journal-title":"Trends Mol Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1210455","article-title":"The rs17782313 polymorphism near MC4R gene confers a high risk of obesity and\n                    hyperglycemia, while PGC1\u03b1 rs8192678 polymorphism is weakly correlated with\n                    glucometabolic disorder: a systematic review and meta-analysis","volume":"14","author":"Y Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref57","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.1038\/s41467-024-50827-7","article-title":"Structure elucidation of a human melanocortin-4 receptor specific orthosteric\n                    nanobody agonist","volume":"15","author":"T Fontaine","year":"2024","journal-title":"Nat Commun"},{"issue":"06","key":"ref58","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/87551225221116010","article-title":"Setmelanotide: A novel targeted treatment for monogenic obesity","volume":"38","author":"H Pressley","year":"2022","journal-title":"J Pharm Technol"},{"issue":"03","key":"ref59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1055\/s-0041-1731035","article-title":"Evaluation and Management of Early Onset Genetic Obesity in Childhood","volume":"10","author":"S Malhotra","year":"2021","journal-title":"J Pediatr Genet"},{"issue":"06","key":"ref60","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/dom.14672","article-title":"Effect of bremelanotide on body weight of obese women: Data from two phase 1\n                    randomized controlled trials","volume":"24","author":"C Spana","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"ref61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"F S Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"01","key":"ref62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2\n                    diabetes with unmatched effectiveness regrading glycaemic control and body\n                    weight reduction","volume":"21","author":"M A Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"01","key":"ref63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine\n                    perspective","volume":"25","author":"C De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1453825","DOI":"10.3389\/fphar.2024.1453825","article-title":"Tirzepatide's innovative applications in\n                    the management of type 2 diabetes and its future prospects in cardiovascular\n                    health","volume":"15","author":"J Yang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"03","key":"ref65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"A M Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"05","key":"ref66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"M Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1309118","article-title":"Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic\n                    patients: a systematic review and meta-analysis of randomized controlled\n                    trials","volume":"15","author":"D L Nalisa","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12020-024-03857-6","article-title":"Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the\n                    treatment of type 2 diabetes and obesity: a systematic review and meta-analysis\n                    of randomized controlled trials","volume":"86","author":"B Deng","year":"2024","journal-title":"Endocrine"},{"issue":"04","key":"ref69","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"A J Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"03","key":"ref70","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual\n                    glucagon\/GLP-1 receptor agonist, compared with placebo and open-label\n                    semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"M Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"issue":"07","key":"ref71","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/dom.15579","article-title":"Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake\n                    in type 2 diabetes with obesity","volume":"26","author":"R Golubic","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"06","key":"ref72","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1\n                    and glucagon receptor agonist cotadutide on kidney outcomes in patients with\n                    diabetic kidney disease","volume":"106","author":"V Selvarajah","year":"2024","journal-title":"Kidney Int"},{"issue":"01","key":"ref73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A\n                    randomized, double-blind, placebo-controlled study","volume":"82","author":"S A Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.metop.2024.100321","article-title":"Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"E Pasqualotto","year":"2024","journal-title":"Metabol Open"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.molmet.2018.09.010","article-title":"Overexpression of melanocortin 2 receptor accessory protein 2 (MRAP2) in adult\n                    paraventricular MC4R neurons regulates energy intake and expenditure","volume":"18","author":"G Bruschetta","year":"2018","journal-title":"Mol Metab"},{"issue":"09","key":"ref76","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of\n                    Type 2 Diabetes","volume":"81","author":"A Andersen","year":"2021","journal-title":"Drugs"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.37765\/ajmc.2020.88554","article-title":"Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and\n                    implications for manage care","volume":"26","author":"H W Rodbard","year":"2020","journal-title":"Am J Manag Care"},{"issue":"01","key":"ref78","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2337\/cd19-0079","article-title":"Oral Semaglutide","volume":"38","author":"S Hughes","year":"2020","journal-title":"Clin Diabetes"},{"issue":"08","key":"ref79","doi-asserted-by":"publisher","first-page":"e2892","DOI":"10.1371\/journal.pone.0002892","article-title":"Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained\n                    glycemic control and weight loss in diabetic mice","volume":"3","author":"H Su","year":"2008","journal-title":"PLoS One"},{"issue":"02","key":"ref80","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1002\/osp4.743","article-title":"Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor\n                    agonist as an anti-obesity medicine: A systematic review and meta-analysis","volume":"10","author":"D Dutta","year":"2024","journal-title":"Obes Sci Pract"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"230469","DOI":"10.20945\/2359-4292-2023-0469","article-title":"Effects of once-daily oral orforglipron on weight and metabolic markers: a\n                    systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"C L\u00fctkemeyer","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"05","key":"ref82","doi-asserted-by":"publisher","first-page":"e2314493","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and Safety of Oral Small Molecule\n                    Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among\n                    Patients With Type 2 Diabetes: A Randomized Clinical\n                    Trial","volume":"6","author":"A R Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"01","key":"ref83","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.16005","article-title":"Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist,\n                    lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2,\n                    randomized, placebo-controlled study","volume":"27","author":"N B Amin","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"01","key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010159","article-title":"The Role of GLP-1, GIP, MCP-1 and IGFBP-7 biomarkers in the development of\n                    metabolic disorders: A review and predictive analysis in the contxt of diabetes\n                    and obesity","volume":"12","author":"M J\u0119drysik","year":"2024","journal-title":"Biomedicines"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221108064","article-title":"Effect of semaglutide and liraglutide in individuals with obesity or overweight\n                    without diabetes: a systematic review","volume":"13","author":"Y Deng","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"issue":"02","key":"ref86","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nn.4202","article-title":"Melanocortin-4 receptor-regulated energy homeostasis","volume":"19","author":"M J Krashes","year":"2016","journal-title":"Nat Neurosci"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pneurobio.2016.11.004","article-title":"Multiple bneficial effects of melanocortin MC(4) receptor agonists in\n                    experimental neurodegenerative disorders: Therapeutic perspectives","volume":"148","author":"D Giuliani","year":"2017","journal-title":"Prog Neurobiol"},{"issue":"02","key":"ref88","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2337\/db12-0598","article-title":"Chronic treatment with a melanocortin-4 receptor agonist causes weight loss,\n                    reduces insulin resistance, and improves cardiovascular function in diet-induced\n                    obese rhesus macaques","volume":"62","author":"P Kievit","year":"2013","journal-title":"Diabetes"},{"issue":"13","key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132023","article-title":"GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unitin the\n                    Spotlight","volume":"11","author":"G Monti","year":"2022","journal-title":"Cells"},{"issue":"07","key":"ref90","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and\n                    mechanisms of action","volume":"20","author":"J R Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"06","key":"ref91","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1","volume":"31","author":"R J Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"171003","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"A Novikoff","year":"2023","journal-title":"Peptides"},{"issue":"01","key":"ref93","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients\n                    Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus","volume":"12","author":"J J Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"ref94","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor","volume":"65","author":"D A Griffith","year":"2022","journal-title":"J Med Chem"},{"issue":"05","key":"ref95","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for\n                    the treatment of type 2 diabetes","volume":"23","author":"V R Aroda","year":"2022","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2928-5204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:41:28Z","timestamp":1789425688000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2928-5204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":94,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2928-5204","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}